For more than a decade, Biogen Inc. worked on a new drug for Alzheimer’s disease that seemed to have blockbuster potential.
Early results were so impressive that Biogen raced toward regulatory approval—a risky gambit that drove up the stock as investors anticipated sales of the first approved drug in nearly two decades to slow the advancement of a disease affecting six million Americans.